DBMR Logo.png
Psychedelic Drugs Market CAGR at +13.3% with Analysis of Growing Technology Trends, Industry Research, Future Growth and Size, Projection by 2028
14 juil. 2021 16h55 HE | Data Bridge Market Research
SAN FRANCISCO, July 14, 2021 (GLOBE NEWSWIRE) -- Psychedelic Drugs Market Research Report gives insightful analysis of the market along with its comprehensive understanding and its commercial...
Algernon Logo 1.png
Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021
17 juin 2021 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that all...
Xphyto logo.jpg
XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies
15 juin 2021 11h10 HE | XPhyto Therapeutics Corp.
VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on...
Algernon Logo 1.png
Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF
29 mars 2021 07h02 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia., March 29, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
Algernon Logo 1.png
Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke
17 mars 2021 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, March 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage...
Algernon Logo 1.png
Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference
25 févr. 2021 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...